{"id":"asc42","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"FXR (Farnesoid X Receptor) activation by ASC42 leads to the regulation of genes involved in bile acid synthesis, transport, and metabolism, which can help reduce liver fat accumulation and inflammation, making it a potential treatment for non-alcoholic steatohepatitis (NASH).","oneSentence":"ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:55:05.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-alcoholic steatohepatitis (NASH)"}]},"trialDetails":[{"nctId":"NCT05118516","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2021-11-01","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT04679129","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2020-11-30","conditions":"Healthy","enrollment":64},{"nctId":"NCT05464628","phase":"PHASE1","title":"Drug Interaction Study of ASC42 With Atorvastatin","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2022-08-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT05190523","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2022-04-06","conditions":"Primary Biliary Cholangitis","enrollment":98},{"nctId":"NCT05107778","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-10","conditions":"Hepatitis B, Chronic","enrollment":43},{"nctId":"NCT04965337","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2021-07-11","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ASC42","genericName":"ASC42","companyName":"Gannex Pharma Co., Ltd.","companyId":"gannex-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation. Used for Non-alcoholic steatohepatitis (NASH).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}